Connecting Biotechnology and

Cannabinoids to treat incurable diseases

click here to invest now

Please note that due to Canadian securities regulations we are not able to accept investments from Canada.

At Emerald Health Pharmaceuticals (EHP), we’re developing new medicines for diseases with no current cure based on unique, cutting-edge cannabinoid science & biotechnology. Our therapies are designed specifically to affect the targets involved in many life-threatening diseases and be potentially disease-modifying rather than for just symptomatic treatment. Our four initial therapeutic areas of focus include multiple sclerosis, systemic sclerosis (a form of scleroderma), Parkinson’s disease and Huntington’s disease.
“We are dedicated to promoting health, improving quality of life, and saving lives through cannabinoid science. Everything we do as a company is focused on achieving this mission. With our experienced team, our world-class advisors, our unique and powerful technology, and the positive results we have accomplished in our studies to date, we are well on our way to realizing our goal of being able to treat many diseases that today have no available cure. In pursuing this mission, the support of our shareholders is invaluable and critical to our success – and we appreciate their commitment.”
– Dr. Jim DeMesa, President and CEO 
Investor Presenatation




Subscription Process
About the ECS
Reg A
Offering Circular
Fact Sheet
About the ECS
About the ECS
In the
Fact Sheet
About the ECS

FAQ – Offering Details

In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A is an exemption from registration requirements under the Securities Act that allows companies to offer and sell their securities without having to register the offering with the SEC. The issuer of a Regulation A offering must give buyers documentation with the issue, similar to the prospectus of a registered offering. For more information, you can visit the SEC Investor Information website at

In order to participate in this opportunity, you will need to invest a minimum of $3,000 USD.

The maximum amount that you can invest as a non-accredited investor is 10% of the greater of your income or net worth. There is no limit for accredited investors.

An accredited investor is an individual who makes over $200,000 per year in income ($300,000 if combined with a spouse) or who has a net worth of $1 million or more, excluding their primary residence. A non-accredited investor is anyone who does not meet at least one of the income or net worth requirements for being considered an accredited investor.

You may click any of the “Invest now” buttons located on the page to initiate the investment process using a secured and encrypted digital form hosted by our escrow agent, Prime Trust, LLC, for purposes of entering your subscriber information and completing the subscription agreement. Through a series of screens you will be prompted to provide the required investor information as well as payment instructions.

In accordance with FINRA regulations and as required by the PATRIOT Act, all issuers must ensure that their investors are compliant with AML (Anti-Money Laundering) and other investor compliance verifications. As such, all questions must be answered completely and accurately in order to complete the subscription agreement.

If you are unable to access the agreement or have additional questions regarding this process, please email us at or call our customer service line at 1-888-468-3471 to speak with an agent.

We accept wire transfers, ACH (electronic check), self-directed IRA and checks for payment.

If you selected “Mail a Check or Wire Transfer” as the payment method, the payment instructions will be displayed on screen upon digitally signing the subscription agreement. You will also receive an email confirmation upon completion of the subscription agreement, which includes these payment instructions. If you do not receive this email, please first check your junk or spam email folder, and then feel free to email us at or call our customer service line at 1-888-468-3471 to speak with a company representative.

There are no fees in order to complete your investment.

We are able to accept investments from all countries, except Canada.

While we do not market in Canada, or solicit investments from Canada, we are aware that regulators from certain Canadian provinces require U.S. companies to comply with Canadian provincial securities laws. If you are Canadian investor interested in this Regulation A+ offering, please email and we will contact you should this investment opportunity become available.

We greatly appreciate your interest in Emerald Health Pharmaceuticals. We have created this page to be your one-stop shop for all the information you may need regarding EHP. We encourage you to watch the investor presentation given by our President and CEO, Dr. Jim DeMesa, and read through this FAQ section. You will also find an in-depth overview of our company starting on page 31 in the Reg A+ Offering Circular. Should you have additional questions about the company, please email us at  or call our customer service line at 1-888-468-3471 to speak with a company agent.

To read more about the current and previous news from EHP, please click here or visit our main website at

If you would like to stay up-to-date on all future company developments, please sign up for our newsletter here.

FAQ – Post Offering

Investment payments are processed by our Escrow Agent, Prime Trust. Prime Trust will be the name that appears on ACH statements.

ACH transactions can take 1-2 business days to process, whereas all other forms of payment could take up to 10 business days to process. You will receive an email notification, from, when your funds are received.

Once funds are received, it can take up to 3 weeks to process your investment completely, with an additional 6-8 weeks from the time funds have been received and cleared for you to receive your paper statement via US mail from Computershare, our transfer agent.

Once your investment has been fully processed and confirmed, you will receive an investment confirmation email with your signed subscription agreement. You are officially a shareholder of Emerald Health Pharmaceuticals when you receive this email.

If a couple of weeks pass by and you do not receive an investor confirmation email with your signed subscription agreement, please email us at We may still require additional information from you in order to process your investment fully. We recommend you check your spam folder first for any email communications!

In some instances, we may reach out to you requesting additional information in order to finish processing your investment, which may increase the overall amount of time it takes to process your investment completely.

Again, please note that it will take 6-8 weeks from the time funds have been received and cleared for you to receive your paper statement via US mail from Computershare, our transfer agent. If 8 weeks have passed and you have not received any communications via US mail, please contact our dedicated customer service team at or call us at 1-888-468-3471. 

The use capital raised from this offering will include but will not be limited to clinical trials and working capital. Please read the ‘Use of Proceeds’ section in our offering curricular for more details on our plans for the future.

Currently there is no market or liquidity for Regulation A+ shares. As an investor in a private company, you typically receive a return on your investment under the following two scenarios:

  1. The company gets acquired by another company.
  2. The company goes public (undergoes an initial public offering on the NASDAQ, NYSE, or another exchange).

SEC regulations do not allow us to comment on if, or when, we will do an IPO. However, it is our intent to create liquidity for shareholders, which can happen by listing our shares on a stock exchange, whether or not it is part of an IPO, or through an acquisition. What we can say is that typically companies who are looking to complete an IPO are influenced by stock market conditions and by the company’s accomplishments and timing of next milestones, and we will weigh these variables accordingly.

For any questions about our offering, please email us at or call our dedicated team at 1-888-468-3471.

FAQ – The Company

Emerald Health Pharmaceuticals (EHP) is developing new pharmaceutical drug candidates by enhancing the known benefits of cannabinoid interactions with the human endocannabinoid system (ECS) to positively impact several serious diseases, including neurodegenerative, autoimmune, inflammatory, metabolic, and fibrotic diseases. Starting from synthetically manufactured cannabinoids, we create new molecules which target the ECS and other relevant receptors that may provide valuable therapeutic benefits against diseases with unmet medical needs.

EHP’s scientists have rationally designed and chemically modified non-psychotropic cannabinoids to affect several validated biological targets and physiological pathways in the body. These targets and pathways have been validated by independent third-party research as being pertinent to the diseases targeted by EHP’s drug product candidates, and our drug candidates have been shown in validated animal disease models to achieve therapeutic benefits that exceed the capabilities of natural cannabinoids.

As new chemical entities (NCEs), EHP’s molecules are protected by 16 issued international patents and 22 pending patents, including composition of matter, covering 25 different molecules.

EHP’s approach is unique. To our knowledge, no other researchers have yet developed a molecule with the ability to target all of the receptors targeted by EHP’s molecules, which provides the opportunity for a more effective and efficient approach to treating a wide range of diseases.

Interested in a technical description? Please read on!

Rational Drug Design: New Chemical Entity (NCE)


EHP-101 is derived from CBD, the most abundant natural cannabinoid. EHP-101 has been modified to enhance the therapeutic benefits of CBD by being a dual PPARγ and CB2 agonist that also activates the hypoxia inducible factor (HIF) pathway. There is evidence that these validated receptors may be beneficial in preventing neuroinflammation and demyelination in the central nervous system and fibrogenesis in the periphery. Based on these activities, Emerald is initially developing this proprietary new drug candidate for multiple sclerosis and scleroderma.

For more information, please visit


EHP-102 is derived from CBG, another abundant natural cannabinoid. CBG has been shown to be anti-inflammatory and shows evidence of neuroprotection. EHP-102 has been modified to provide even more potent benefits compared to CBG by also affecting PPARγ, a key molecular target for the treatment of Huntington’s disease, as well as targeting other pathways involved in neural survival. These characteristics have led EHP to develop this proprietary new drug candidate for Huntington’s disease and Parkinson’s disease.

For more information, please visit

Our medicines initially target four diseases: multiple sclerosis, Parkinson’s disease, scleroderma and Huntington’s disease. These diseases represent a combined $38 billion market and a huge unmet medical need, as there is no cure.

Multiple Sclerosis

Multiple sclerosis is an inflammatory and demyelinating disorder of the central nervous system affecting 2.3 million people worldwide. Myelin is a sheath around nerves that aids in conducting nerve impulses. Demyelination is a breakdown of this sheath. It is not reversible naturally or through existing drugs. As MS progresses, it causes pain affecting muscles, nerves, and joints, spasms, stiffness, and tremors, body mobility limitations and weakness, difficulty chewing or swallowing, in addition to speech difficulties.

Currently, there are several approved drugs on the market, all of which, are primarily for the relief of symptoms and none are disease-modifying or curative. Our preclinical data suggest that EHP-101 has the potential to be neuroprotective and disease-modifying, which could potentially be a significant advantage in the market.

Market value: US $16.3B in 2016; expected to reach US $27.38B by 2025.

Parkinson’s Disease (PD)

Parkinson’s disease is an incurable neurodegenerative disorder affecting nearly 10 million people worldwide. Primarily, it is a disease where the nerve cells stop producing a substance called dopamine, which helps transmit impulses from the brain to the muscles. It results in tremors, slowness and stiffness, impaired balance, and rigidity of the muscles. These symptoms get worse over time.

Currently, there is no cure for Parkinson’s disease, however, preclinical data show the potential of our drug, EHP-102, to provide neuroprotection and antiinflammation to improve clinical outcomes.  Additionally, our treatment has shown the potential to reduce the loss of production of dopamine, the main issue with Parkinson’s disease.

Market value: US $2.15B in 2016; expected to reach US $5.24B by 2025.

Scleroderma (Systemic Sclerosis or SSc)

Scleroderma is an autoimmune disease that causes fibrosis, or thickening and scarring, of skin and internal organs.  There is currently no cure and it is classified as an orphan disease in the US and EU. It is classified as an orphan disease (under 200,000 patients in a jurisdiction) in the US and EU.

Currently, there is no cure for scleroderma and approved therapies on the market today only address symptoms and are highly toxic. Our preclinical data in scleroderma suggests that EHP-101 may positively affect multiple anti-fibrotic pathways. Additionally, EHP-101 has been granted Orphan Drug Designation by the FDA in the United States and the EMA in Europe.

Market value: US $1.68B in 2017; expected to reach US $3.66B by 2024.

Huntington’s Disease (HD)

Huntington’s disease is an inherited disease that causes the progressive breakdown of nerve cells. It deteriorates patients’ physical and mental abilities to the extent that they are unable to care for themselves. It has no cure. In the U.S., approximately 30,000 people are symptomatic and more than 200,000 are at risk of inheriting the disease.

Currently, there are no drugs to slow or stop the progression of Huntington’s disease. There are specific drugs available to reduce some of the symptoms. Our preclinical data suggest that the neuroprotective potential of EHP-102 may provide a significant opportunity in the market. Additionally, EHP-102 has been granted Orphan Drug Designation by the FDA in the United States and EMA in Europe.

Market value: US $252.6M in 2014; expected to reach US $2.6B by 2024.

Our work in cannabinoid science has been well-received by the scientific community and published by independent, credible scientific journals. Below you will find links to several publications that review the advances we’ve made in the development of new chemical entities for the treatment of neurogenerative, autoimmune and CNS diseases.

Multiple Sclerosis

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy” Journal of Neuroinflammation (2018) 15:64 DOI 10.1186/s12974-018-1103-y Authors: Carmen Navarrete, Francisco Carrillo-Salinas, Belén Palomares, Miriam Mecha, Carla Jiménez-Jiménez, Leyre Mestre, Ana Feliú, Maria L. Bellido, Bernd L. Fiebich, Giovanni Appendino, Marco A. Calzado, Carmen Guaza and Eduardo Muñoz

A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis”. PLoS One (2014) 9(4): e94733, DOI: 10.1371/journal.pone.0094733. Authors: Francisco J. Carrillo-Salinas, Carmen Navarrete, Mirian Mecha M, Ana Feliú, Juan A. Collado, Irene Cantarero, Maria L. Bellido, Eduardo Muñoz and Carmen Guaza.

A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis”. Journal of Neuroimmune Pharmacology. (2012) 4:1002-1016, DOI: 10.1007/s11481-012-9399-3. Authors: Aitor G. Granja, Francisco Carrillo-Salinas, Alberto Pagani, María Gómez-Cañas, Roberto Negri, Carmen Navarrete, Miriam Mecha, Leyre Mestre, Bernd L. Fiebich, Irene Cantarero, Marco A. Calzado, Maria L. Bellido, Javier Fernandez-Ruiz, Giovanni Appendino, Carmen Guaza and Eduardo Muñoz.


Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis”. Biochemical Pharmacology (2019) 163:321-334 DOI: 10.1016/j.bcp.2019.02.029. Authors: Adela García-Martín, Martín Garrido-Rodríguez, Carmen Navarrete, Diego Caprioglio, Belén Palomares, Jim DeMesa, Alain Rolland, Giovanni Appendino, and Eduardo Muñoz

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis”. Biochemical Pharmacology (2018) 157:304-313, DOI: 10.1016/j.bcp.2018.07.047. Authors: Adela García-Martín, M. Garrido-Rodríguez, Carmen Navarrete, Carmen Del Río C, Maria L. Bellido, Giovanni Appendino, Marco A. Calzado and Eduardo Muñoz.

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways”. Scientific Report (2016) 6:21703, DOI. 10.1038/srep21703. Authors: Carmen del Río, Carmen Navarrete, Juan A.  Collado, M. Luz Bellido, María Gómez-Cañas, M. Ruth Pazos, Javier Fernández-Ruiz, Federica Pollastro, Giovanni Appendino, Marco A. Calzado, Irene Cantarero and Eduardo Muñoz.

Parkinson’s Disease

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor” Journal of Neuroinflammation (2018) 15:19 DOI 10.1186/s12974-018-1060-5 Authors: Concepción García, María Gómez-Cañas, Sonia Burgaz, Belén Palomares, Yolanda Gómez-Gálvez, Cristina Palomo-Garo, Sara Campo, Joel Ferrer-Hernández, Carolina Pavicic, Carmen Navarrete, M. Luz Bellido, Moisés García-Arencibia, M. Ruth Pazos, Eduardo Muñoz and Javier Fernández-Ruiz

Development of An oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease”. Molecules (2019) 24(15). pii: E2702, DOI: 10.3390/molecules24152702. Authors: Sonia Burgaz, Concepción García, Maria Gómez-Cañas, Eduardo Muñoz and Javier Fernández-Ruiz.

Huntington’s Disease

VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease“.  Scientific Report (2016) July 19;6:29789. Authors: Javier Díaz-Alonso, Juan Paraíso-Luna, Carmen Navarrete, Carmen del Río, Irene Cantarero, Belén Palomares, José Aguareles, Javier Fernández-Ruiz, María Luz Bellido, Federica Pollastro, Giovanni Appendino, Marco A. Calzado, Ismael Galve-Roperh, Eduardo Muñoz.

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration” Translational Neurodegeneration (2019) 8:9 DOI:10.1186/s40035-019-0148-x Authors: José Aguareles, Juan Paraíso-Luna, Belén Palomares, Raquel Bajo-Grañeras, Carmen Navarrete, Andrea Ruiz-Calvo, Daniel García-Rincón, Elena García-Taboada, Manuel Guzmán, Eduardo Muñoz and Ismael Galve-Roperh

EHP-101 is a first-in-class, potentially disease-modifying therapy, initially targeting multiple sclerosis and scleroderma. It is a new drug that leverages the known benefi­ts of cannabis molecules called cannabinoids by modifying them to also target other validated disease-related pathways that may have beneficial impacts on those diseases. EHP-101 has been shown to be safe, anti-inflammatory, neuroprotective, pain relieving, preventative of growth and/or spreading, and to reduce clinical signs of disease progression in preclinical models. A Phase 2 clinical trial of  EHP-101  in systemic sclerosis patients (a severe form of scleroderma) is currently under way in Australia.

For more information, please visit

EHP-102 is an oral pharmaceutical product candidate derived from cannabigerol (CBG), another key cannabinoid molecule. CBG has been shown to be anti-inflammatory and shows evidence of neuroprotection. The novel active molecule of EHP-102 has been modified to provide even more potent effects compared to CBG by also affecting PPARγ, a key molecular target for the treatment of Huntington’s and Parkinson’s diseases, as well as other pathways involved in the pathophysiology of neurodegenerative diseases. These characteristics have led EHP to develop this proprietary new drug candidate for Huntington’s disease and Parkinson’s disease.

For more information, please visit 

We create our new molecules by incorporating known chemical components into the cannabidiol (CBD) and cannabigerol (CBG) molecule, which results in our novel molecules. Here is some background and then some details on why and how we have created these new molecules.

First the “why”: Cannabinoids like CBD and CBG have many known health benefits, as widely observed anecdotally and, with CBD, now proven in clinical trials for specific rare types of childhood epilepsy. Our strategy has been to create therapeutic capabilities far beyond what CBD and CBG alone can do. The goal has been to enhance the beneficial effects of CBD and CBG and create other potential treatment benefits toward specific target disease categories such as inflammatory, autoimmune, neurodegenerative and fibrotic diseases. We set off on this journey with the knowledge that there are biological receptors and physiologic pathways, both within and outside of the endocannabinoid system (ECS), specifically, CB2 receptors (part of the ECS), PPARγ receptors, and the HIF pathway, that have been validated by independent researchers as key targets for these important therapeutic disease categories. Our scientists also had the knowledge that there are known chemical structures that are able to interact with these receptors and pathways in a manner that can increase or decrease their functions in a way that is beneficial with respect to the activity and progression of such diseases. So, knowing this, our scientists employed what is called rational drug design and standard chemistry methods to add these chemical modifications to CBD and CBG molecules. They were successful in creating these novel molecules with expanded effects and, importantly, demonstrating their effects in several preclinical studies related to various diseases, including multiple sclerosis (MS) and systemic sclerosis (SSc), a severe form of scleroderma.

Now the “how”: As shown in the diagram below, the active molecules in EHP-101 and EHP-102 are created by adding what’s called a quinone group to the central ring (called a benzene ring) of the CBD molecule for EHP-101 and the CBG molecule for EHP-102, and by adding what is called an amino group to the right side of that benzene ring for both CBD and CBG (although the amino groups are different for EHP-101 and EHP0-102). These are components used in organic chemistry to produce new chemical entities. These changes to CBD and CBG create new molecules that are patented by EHP, and as mentioned previously, add significant therapeutic properties which CBD and CBG do not effect.

Emerald Health Pharmaceuticals is a clinical development stage company. Our Phase 2 clinical trial of EHP-101 in systemic sclerosis patients (a severe form of scleroderma) is currently underway in Australia and the US.  Below you will find an image of our clinical development pipeline for your reference:

We have extensive preclinical data demonstrating that EHP-101 can succeed in SSc. In validated SSc animal models, relevant therapeutic benefits were seen with EHP-101 in reducing both inflammation and fibrosis, which is the tissue thickening and scarring that are the main issues with SSc, as well as promoting the protection and regeneration of the vasculature, which is important in treating systemic sclerosis.

There are three other reasons to start Phase 2 in SSc first:

1. With SSc, we can do an initial Phase 2a study with a short 3-month treatment period. For MS, a 6-month initial study is necessary, which requires additional nonclinical toxicology studies before initiating Phase 2 to allow for the longer treatment duration. We are currently doing those toxicology studies, with expected completion in the third quarter of this year. We then plan to start the MS studies after those studies are finished. Essentially, we can therefore start the study and get Phase 2 results much more quickly with SSc as compared to MS;

2. Since SSc has many of the same validated targets in the body as MS, quicker positive data in SSc clinical studies can give us some evidence that EHP-101 could also work in MS; and

3. SSc is a rare disease, for which we have been granted both Orphan designation in the US and EU and Fast Track status by the FDA. This provides many advantages to the clinical development process, such as more frequent interactions with the FDA, various tax credits for clinical studies, as well as 7-years of market exclusivity once approved due to the Orphan designation.

Based on these factors, as well as the multiple organs affected by the disease, SSc represents the quickest path to key value-driving proof-of-concept efficacy data, and it also requires less capital to complete the Phase 2a trial. If all goes as currently planned, we expect to start getting preliminary results from the SSc Phase 2a study by the end of 2020 and into 2021. Positive data in Phase 2 can also help validate the mechanism of action of EHP-101, supporting its potential to treat other fibrotic and demyelinating diseases, including MS (our other disease indication for EHP-101). This is possible because EHP-101 was designed specifically to address validated targets in the body that are related to various diseases. MS and SSc share some of the same validated targets, so in the SSc Phase 2a study, which we are now initiating, if we demonstrate efficacy and can support the MoA related to the relevant receptors and pathways in the body, the same can potentially occur in other fibrotic diseases and also in various demyelinating diseases (like MS) since they also share some of the same targets. We have already proven this in our many preclinical studies.

At this time there is still much unknown surrounding the current situation with COVID-19 and how it might affect clinical studies. It is likely that the current circumstances could cause a temporary delay in conducting clinical studies, mainly for the safety of the people involved in managing the study as well as the patients participating in the study. However, based on what we know at this time, as well as everything being discussed with regulatory agencies, and everything we are doing remotely to continue initiating the study, if there is a delay, it should only be temporary.

To launch a clinical study, approval must be granted from the regulatory agencies in the countries where the study is being conducted. These approvals allow for the setup of clinical sites with the clinical investigators at each site. Patients can then be enrolled into the study once they meet the entry criteria for the study, which is when treatment can begin.

We have received the regulatory approvals from health authorities that we need to start the study. We have sites identified (as a reminder, we plan to have approximately 30 sites for this SSc Phase 2a study in Australia, New Zealand and the US) and are proceeding with the formal setup. Some patients have already been identified and the screening process can be initiated, followed by the start of treatment once it is safe to do so.

The bottom line is we are in close communication with the clinical investigators at the sites to make sure everything is organized and moving forward as quickly as possible. So be assured that we are doing whatever it takes to minimize any delays, without risking people’s health, and are ready to start treatment as soon as it is safe, which is hopefully very soon. Based on all of this, we can still have preliminary results from our Phase 2a study around the end of the year, or the beginning of 2021, if all goes as planned.

Clinical trials for new treatments are always tested through several steps called phases. The typical phases of clinical trials are:

Phase 1: Safety

Phase 1 focuses on the safety of a drug. It is usually conducted with healthy volunteers with the goal to determine the drug’s most frequent and serious adverse events, at what dose level and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.

Phase 2: Safety & Efficacy

A Phase 2 clinical trial is used to gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug’s effectiveness). Participants receiving the drug may be compared to similar participants receiving an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated and short-term adverse events are studied. Phase 2 trials are usually fewer than 100 people in participation.

Phase 3: Safety & Efficacy

Phase 3 gathers more information about a drug’s safety and effectiveness by studying different populations with what would be considered a drug, drug combination, and dosage that might be used in the clinic (ie commercially). The drug being studied is compared to a placebo or competitive drug and uses very high standards to ensure the quality of the results – (commonly used elements of high-quality clinical study design are include being randomized, double-blind, and placebo-controlled.) Phase 3 trials may include people from all over the world. The usual number of people in the trial is several hundred to several thousand.

A Phase 3 study is typically undertaken only with expectation that the drug and study design have a good prospect of proving the drug’s clinical utility and being given regulatory and marketing approval by an agency such as the US Food and Drug Administration (FDA).

Phase 4: Additional Research

Phase 4 is sometimes initiated after the FDA has approved a drug for marketing. These trials gather additional information about a drug’s safety, efficacy, or optimal use.

We are often asked whether it is possible to become part of one of our clinical studies. Unfortunately, we are unable to take volunteers to participate in our current clinical trial of EHP-101. However, if you would like to learn more about our development progress, please send us an email:

At this time we are not recruiting patients, once the study is open for recruitment we will update the website. We have received approval to begin the study and expect to start enrolling patients within the next couple of months, so we are on track. Please note that our first research centers for this Phase 2 clinical trial of EHP-101 for the treatment of systemic sclerosis will be located in Australia and we will expand into the US later in the year.

You may find the eligibility criteria on the website by clicking here, however you will need to speak directly with your doctor to determine eligibility. Additionally, you or your doctor may contact the study research staff using the contacts provided on the website to learn more information.

Emerald Health Pharmaceuticals is making great strides in advancing its mission to develop cannabinoid-based medicines for the treatment of deadly diseases. To read more about the current and previous news from EHP, please click here or visit our main website at

Additionally, if you would like to stay up-to-date on all future company developments, please sign up for our newsletter here. 

Still have questions?

You may also reach us via email or by filling out the online form.

Our customer service hours of operation are from 7am – 6pm PT, Monday to Friday and 7am – 12pm PT Saturday.